Isovurex

Ezetimibe, the active ingredient in Isovurex, is a cholesterol absorption inhibitor presented as an oral tablet for oral administration. It reduces elevated low‑density lipoprotein cholesterol in adults with primary hyperlipidemia, heterozygous or homozygous familial hypercholesterolemia, and related lipid disorders.

GNH USA supplies Isovurex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution across EU and other markets, and the company adheres to stringent quality standards and provides regulatory support for importers and healthcare providers globally.

Ezetimibe is used to lower cholesterol by inhibiting intestinal absorption, and is indicated for several lipid disorders.

Hypercholesterolemia: reduces LDL‑C levels in patients with elevated cholesterol. Heterozygous familial hypercholesterolemia: lowers LDL‑C in individuals with a single defective LDLR gene. Homozygous familial hypercholesterolemia: provides cholesterol reduction in patients with two defective LDLR genes. Primary hyperlipidemia: improves overall lipid profile in adults with elevated triglycerides and cholesterol.

Adverse reactions may occur with ezetimibe therapy.

Common Side Effects: - Abdominal pain - Diarrhea - Fatigue - Headache - Nausea - Muscle pain

Serious or Rare Side Effects: - Hepatitis or severe liver injury - Rhabdomyolysis, especially when combined with statins - Severe allergic reactions (e.g., angioedema, anaphylaxis) - Cholestatic jaundice - Pancreatitis - Myopathy with marked CK elevation

Before initiating therapy, several safety considerations are recommended.

Monitor liver function: obtain baseline hepatic enzymes and repeat periodically. Assess baseline lipid profile: document LDL‑C levels prior to treatment. Use with statins cautiously: consider dose adjustments and monitor for muscle toxicity. Avoid in active liver disease: contraindicated in patients with unexplained persistent elevations of transaminases. Pregnancy and lactation: only if potential benefit outweighs risk, as data are limited. Store at room temperature: keep below 25 °C in the original packaging, protect from moisture and direct sunlight.

Ezetimibe may interact with several medicines; awareness of interaction severity guides management.

Major Interactions (Avoid): - Cyclosporine: increases ezetimibe plasma concentrations. - Antifungal azoles (e.g., ketoconazole): may raise ezetimibe levels. - Bile‑acid sequestrants: reduce ezetimibe absorption when taken concurrently.

Moderate Interactions (Monitor Closely): - Statins: combined use can increase risk of myopathy; monitor CK. - Warfarin: possible alteration of INR; check coagulation status. - Niacin: may enhance risk of hepatic toxicity; monitor liver enzymes.